Effect of Selexipag on Daily Life Physical Activity of Patients With Pulmonary Arterial Hypertension.

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 108 participants.

Also called NCT03078907

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose other
Phase
Phase 4
Enrolled
  • 108 participants (enrolled count) (from the registry)
Sponsor
  • Actelion Registry lists this organization as the lead sponsor
Registry
  • NCT NCT03078907
Other papers using this trial's data
  • Assessing Daily Life Physical Activity by Actigraphy in Pulmonary Arterial Hypertension: Insights From the Randomized Controlled Study With Selexipag (TRACE) Chest, 2023-02 DOI, PubMed 36089068, PMC9899640 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Austria, France, Germany, Ireland, Norway, Portugal, Sweden, Switzerland, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03078907. Randomized; quadruple masking; primary purpose other. Start 2017-11-08 (actual); primary completion 2020-02-10 (actual). Results posted on 2021-02-23.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Selexipag on Daily Life Physical Activity of Patients With Pulmonary Arterial Hypertension.
Acronym
TRACE
Condition
Pulmonary Arterial Hypertension
Intervention (Drug)
Selexipag
Intervention (Drug)
Placebo
Lead sponsor
Actelion (class: industry)

Record details

Record id
cardio:ct-nct03078907
Content hash
cbe0ed907b67dbedbb020105a548f02eb958bf45ce71aa85c28461e8b9ffe116